Skip to main content

Table 4 Univariate analysis of overall survival (OS)

From: Comparison of weekly administration of cisplatin versus three courses of cisplatin 100 mg/m2 for definitive radiochemotherapy of locally advanced head-and-neck cancers

 

At 1 year (%)

At 3 years (%)

P

Radiochemotherapy regimen

 Cisplatin weekly (N = 75)

71

45

 

 Cisplatin 100 mg/m2 (N = 58)

83

60

0.026

Age

 ≤56 years (N = 67)

77

54

 

 ≥57 years (N = 66)

74

49

0.50

Gender

 Female (N = 29)

89

70

 

 Male (N = 104)

72

47

0.050

ECOG Performance score

 0–1 (N = 115)

78

56

 

 2 (N = 18)

61

14

0.006

Primary tumor site

 Oropharynx (N = 69)

78

61

 

 Hypopharynx (N = 19)

53

21

 

 Larynx (N = 30)

83

59

 

 Oral cavity/Floor of mouth (N = 15)

80

29

<0.001

T-category

 T1–2 (N = 16)

81

63

 

 T3–4 (N = 117)

75

50

0.85

N-category

 N0-2a (N = 66)

79

60

 

 N2b-3 (N = 67)

73

42

0.14

Histologic grading

 G 1–2 (N = 85)

78

52

 

 G3 (N = 48)

73

51

0.47

Cumulative cisplatin dose

 ≤ 200 mg/m2 (N = 85)

69

46

 

 > 200 mg/m2 (N = 48)

87

61

0.13

  1. After Bonferroni correction for multiple tests, p-values of <0.006 were considered significant
  2. Bold values represent significant p-values
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us